CA2842635A1 - Cellules precancereuses et leur identification dans la prevention et le traitement du cancer - Google Patents
Cellules precancereuses et leur identification dans la prevention et le traitement du cancer Download PDFInfo
- Publication number
- CA2842635A1 CA2842635A1 CA2842635A CA2842635A CA2842635A1 CA 2842635 A1 CA2842635 A1 CA 2842635A1 CA 2842635 A CA2842635 A CA 2842635A CA 2842635 A CA2842635 A CA 2842635A CA 2842635 A1 CA2842635 A1 CA 2842635A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- dnmt3a
- mutation
- cancer
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 50
- 201000011510 cancer Diseases 0.000 title claims description 42
- 238000011282 treatment Methods 0.000 title claims description 15
- 230000002265 prevention Effects 0.000 title claims description 9
- 230000035772 mutation Effects 0.000 claims abstract description 114
- 238000000034 method Methods 0.000 claims abstract description 48
- 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 claims abstract description 38
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 claims abstract description 38
- 239000013610 patient sample Substances 0.000 claims abstract description 23
- 238000012216 screening Methods 0.000 claims abstract description 14
- 210000004027 cell Anatomy 0.000 claims description 125
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 45
- 239000000523 sample Substances 0.000 claims description 27
- 208000032839 leukemia Diseases 0.000 claims description 22
- 210000003643 myeloid progenitor cell Anatomy 0.000 claims description 17
- 238000011275 oncology therapy Methods 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 210000004369 blood Anatomy 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 9
- 210000003714 granulocyte Anatomy 0.000 claims description 7
- 238000002512 chemotherapy Methods 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 210000001616 monocyte Anatomy 0.000 claims description 6
- 102200157094 rs147001633 Human genes 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 4
- 210000004698 lymphocyte Anatomy 0.000 claims description 4
- 238000012544 monitoring process Methods 0.000 claims description 3
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 241000237519 Bivalvia Species 0.000 claims 1
- 235000020639 clam Nutrition 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 100
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 97
- 108700028369 Alleles Proteins 0.000 description 35
- 238000003745 diagnosis Methods 0.000 description 35
- 241000282414 Homo sapiens Species 0.000 description 24
- 238000011304 droplet digital PCR Methods 0.000 description 22
- 210000005259 peripheral blood Anatomy 0.000 description 20
- 239000011886 peripheral blood Substances 0.000 description 20
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 18
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 18
- 210000001744 T-lymphocyte Anatomy 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 15
- 210000001185 bone marrow Anatomy 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 210000000130 stem cell Anatomy 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- 101001109719 Homo sapiens Nucleophosmin Proteins 0.000 description 10
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 10
- 102100022678 Nucleophosmin Human genes 0.000 description 10
- 238000012163 sequencing technique Methods 0.000 description 10
- 238000000684 flow cytometry Methods 0.000 description 9
- 210000000135 megakaryocyte-erythroid progenitor cell Anatomy 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 238000003556 assay Methods 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 238000002054 transplantation Methods 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 6
- 101000653374 Homo sapiens Methylcytosine dioxygenase TET2 Proteins 0.000 description 6
- 102100030803 Methylcytosine dioxygenase TET2 Human genes 0.000 description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 210000000066 myeloid cell Anatomy 0.000 description 6
- 206010069754 Acquired gene mutation Diseases 0.000 description 5
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 5
- 230000002860 competitive effect Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 201000000050 myeloid neoplasm Diseases 0.000 description 5
- 210000000822 natural killer cell Anatomy 0.000 description 5
- 238000007480 sanger sequencing Methods 0.000 description 5
- 230000000392 somatic effect Effects 0.000 description 5
- 230000037439 somatic mutation Effects 0.000 description 5
- 206010000830 Acute leukaemia Diseases 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 208000036676 acute undifferentiated leukemia Diseases 0.000 description 4
- 230000003394 haemopoietic effect Effects 0.000 description 4
- 230000002489 hematologic effect Effects 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 230000000306 recurrent effect Effects 0.000 description 4
- 230000003319 supportive effect Effects 0.000 description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 3
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 3
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 3
- 240000007817 Olea europaea Species 0.000 description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 3
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 3
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- JJWKPURADFRFRB-UHFFFAOYSA-N carbonyl sulfide Chemical compound O=C=S JJWKPURADFRFRB-UHFFFAOYSA-N 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000011132 hemopoiesis Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 210000004976 peripheral blood cell Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000002689 xenotransplantation Methods 0.000 description 3
- 101001042041 Bos taurus Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Proteins 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 108010043471 Core Binding Factor Alpha 2 Subunit Proteins 0.000 description 2
- -1 DNMT3a Proteins 0.000 description 2
- 102100039788 GTPase NRas Human genes 0.000 description 2
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 2
- 101000960234 Homo sapiens Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 description 2
- 101000708766 Homo sapiens Structural maintenance of chromosomes protein 3 Proteins 0.000 description 2
- 102100039905 Isocitrate dehydrogenase [NADP] cytoplasmic Human genes 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 2
- 108700019961 Neoplasm Genes Proteins 0.000 description 2
- 102000048850 Neoplasm Genes Human genes 0.000 description 2
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 208000017414 Precursor T-cell acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000007660 Residual Neoplasm Diseases 0.000 description 2
- 102100025373 Runt-related transcription factor 1 Human genes 0.000 description 2
- 102100032723 Structural maintenance of chromosomes protein 3 Human genes 0.000 description 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 2
- OKKRPWIIYQTPQF-UHFFFAOYSA-N Trimethylolpropane trimethacrylate Chemical compound CC(=C)C(=O)OCC(CC)(COC(=O)C(C)=C)COC(=O)C(C)=C OKKRPWIIYQTPQF-UHFFFAOYSA-N 0.000 description 2
- 210000003969 blast cell Anatomy 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 238000013412 genome amplification Methods 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 230000002122 leukaemogenic effect Effects 0.000 description 2
- 238000007798 limiting dilution analysis Methods 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000002629 repopulating effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 229940124598 therapeutic candidate Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- JCJIZBQZPSZIBI-UHFFFAOYSA-N 2-[2,6-di(propan-2-yl)phenyl]benzo[de]isoquinoline-1,3-dione Chemical compound CC(C)C1=CC=CC(C(C)C)=C1N(C1=O)C(=O)C2=C3C1=CC=CC3=CC=C2 JCJIZBQZPSZIBI-UHFFFAOYSA-N 0.000 description 1
- 101150000157 ARHGEF1 gene Proteins 0.000 description 1
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 1
- 239000012114 Alexa Fluor 647 Substances 0.000 description 1
- 208000025321 B-lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 101000963440 Bacillus subtilis (strain 168) Biotin carboxylase 1 Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101100396617 Candida albicans (strain SC5314 / ATCC MYA-2876) IHD1 gene Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 206010065163 Clonal evolution Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102100024812 DNA (cytosine-5)-methyltransferase 3A Human genes 0.000 description 1
- 108010024491 DNA Methyltransferase 3A Proteins 0.000 description 1
- 101100285903 Drosophila melanogaster Hsc70-2 gene Proteins 0.000 description 1
- 101100353161 Drosophila melanogaster prel gene Proteins 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 244000182067 Fraxinus ornus Species 0.000 description 1
- 235000002917 Fraxinus ornus Nutrition 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 208000022435 Light chain deposition disease Diseases 0.000 description 1
- 241001446467 Mama Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102100039373 Membrane cofactor protein Human genes 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 101150085390 RPM1 gene Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 101100348089 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) BUR6 gene Proteins 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 244000180577 Sambucus australis Species 0.000 description 1
- 235000018734 Sambucus australis Nutrition 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102100038123 Teneurin-4 Human genes 0.000 description 1
- 101710122302 Teneurin-4 Proteins 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 210000001357 hemopoietic progenitor cell Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 238000000506 liquid--solid chromatography Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 101150055452 lsc gene Proteins 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000004503 metal oxide affinity chromatography Methods 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 238000001167 microscope projection photolithography Methods 0.000 description 1
- 230000036438 mutation frequency Effects 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 231100001221 nontumorigenic Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 201000002628 peritoneum cancer Diseases 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 238000009258 post-therapy Methods 0.000 description 1
- 208000017426 precursor B-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 230000001855 preneoplastic effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229940087463 proleukin Drugs 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 201000003804 salivary gland carcinoma Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000012731 temporal analysis Methods 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- KUAZQDVKQLNFPE-UHFFFAOYSA-N thiram Chemical compound CN(C)C(=S)SSC(=S)N(C)C KUAZQDVKQLNFPE-UHFFFAOYSA-N 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 208000012991 uterine carcinoma Diseases 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000007482 whole exome sequencing Methods 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461929420P | 2014-01-20 | 2014-01-20 | |
| US61/929,420 | 2014-01-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2842635A1 true CA2842635A1 (fr) | 2015-07-20 |
Family
ID=53675735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2842635A Abandoned CA2842635A1 (fr) | 2014-01-20 | 2014-02-11 | Cellules precancereuses et leur identification dans la prevention et le traitement du cancer |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2842635A1 (fr) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017096150A1 (fr) * | 2015-12-04 | 2017-06-08 | Agios Pharmaceuticals, Inc. | Procédés de traitement de tumeurs malignes |
| WO2017146794A1 (fr) * | 2016-02-26 | 2017-08-31 | Celgene Corporation | Inhibiteurs d'idh2 pour le traitement de tumeurs solides et malignes hématologiques |
| WO2021237609A1 (fr) * | 2020-05-28 | 2021-12-02 | Tsinghua University | Nouvelle utilisation d'oridonine ou d'un dérivé d'oridonine |
-
2014
- 2014-02-11 CA CA2842635A patent/CA2842635A1/fr not_active Abandoned
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017096150A1 (fr) * | 2015-12-04 | 2017-06-08 | Agios Pharmaceuticals, Inc. | Procédés de traitement de tumeurs malignes |
| US10188656B2 (en) | 2015-12-04 | 2019-01-29 | Agios Pharmaceuticals, Inc. | Methods of treatment of malignancies |
| WO2017146794A1 (fr) * | 2016-02-26 | 2017-08-31 | Celgene Corporation | Inhibiteurs d'idh2 pour le traitement de tumeurs solides et malignes hématologiques |
| IL261333A (en) * | 2016-02-26 | 2018-10-31 | Celgene Corp | Idh2 inhibitors for the treatment of haematological maligancies and solid tumours |
| US10137130B2 (en) | 2016-02-26 | 2018-11-27 | Celgene Corporation | Methods of treatment of malignancies |
| WO2021237609A1 (fr) * | 2020-05-28 | 2021-12-02 | Tsinghua University | Nouvelle utilisation d'oridonine ou d'un dérivé d'oridonine |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shlush et al. | Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia | |
| Mathew et al. | Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells | |
| Bahr et al. | A Myc enhancer cluster regulates normal and leukaemic haematopoietic stem cell hierarchies | |
| Sloma et al. | Insights into the stem cells of chronic myeloid leukemia | |
| Park et al. | Musashi2 sustains the mixed-lineage leukemia–driven stem cell regulatory program | |
| Rampal et al. | Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms | |
| Lazarian et al. | Clinical implications of novel genomic discoveries in chronic lymphocytic leukemia | |
| Guo et al. | Suppression of leukemia development caused by PTEN loss | |
| Filip et al. | Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLL—another piece in the puzzle | |
| Shlush et al. | AML evolution from preleukemia to leukemia and relapse | |
| WO2014190035A2 (fr) | Compositions et procédés d'identification, d'estimation, de prévention et de traitement du cancer à l'aide de biomarqueurs et de modulateurs d'histone h3k27me2 | |
| WO2017165412A2 (fr) | Régulateurs de l'expression génique spécifiques à l'état d'épuisement des lymphocytes t et leurs utilisations | |
| Majeti | Clonal evolution of pre-leukemic hematopoietic stem cells precedes human acute myeloid leukemia | |
| Cheng et al. | Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma | |
| Suske et al. | Hyperactive STAT5 hijacks T cell receptor signaling and drives immature T cell acute lymphoblastic leukemia | |
| Jeong et al. | Tumor-infiltrating neutrophils and non-classical monocytes may be potential therapeutic targets for HER2negative gastric cancer | |
| Gniadecki et al. | Haematogenous seeding in mycosis fungoides and Sézary syndrome: current evidence and clinical implications | |
| Routh et al. | Transcriptomic features of T cell-barren tumors are conserved across diverse tumor types | |
| Stölzel et al. | Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia | |
| Bäumer et al. | Proteinase-Activated Receptor 1 (PAR1) regulates leukemic stem cell functions | |
| Testa et al. | Clonal hematopoiesis: role in hematologic and non-hematologic malignancies | |
| Cosentino et al. | Dissecting clonal hematopoiesis in the myeloid compartment of chronic lymphocytic leukemia and Richter transformation | |
| Lai et al. | Cell fate decisions in malignant hematopoiesis: leukemia phenotype is determined by distinct functional domains of the MN1 oncogene | |
| Olbertova et al. | Telomere dynamics in adult hematological malignancies | |
| Song et al. | Co-mutation of ASXL1 and SF3B1 predicts poorer overall survival than isolated ASXL1 or SF3B1 mutations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |
Effective date: 20170213 |